Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

Compare

23 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VX1 Analyst Ratings

Strong Buy

21 Buy

4 Hold

0 Sell

Based on 25 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VX1 Stock 12 Month Forecast

Average Price Target

€462.03

▲(10.57% Upside)

Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €462.03 with a high forecast of €527.72 and a low forecast of €372.36. The average price target represents a 10.57% change from the last price of €417.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"329":"€329","528":"€528","378.75":"€378.8","428.5":"€428.5","478.25":"€478.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":527.72498125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€527.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":462.033775584,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€462.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":372.36274677,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€372.36</span>\n  </div></div>","useHTML":true}}],"tickPositions":[329,378.75,428.5,478.25,528],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,398,407.97884471153844,417.95768942307694,427.9365341346154,437.9153788461539,447.8942235576923,457.87306826923077,467.85191298076927,477.8307576923077,487.80960240384616,497.78844711538466,507.7672918269231,517.7461365384615,{"y":527.72498125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,398,402.9256750449231,407.85135008984616,412.77702513476925,417.70270017969233,422.6283752246154,427.5540502695385,432.4797253144616,437.4054003593846,442.3310754043077,447.25675044923076,452.18242549415385,457.10810053907693,{"y":462.033775584,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,398,396.02790359769233,394.0558071953846,392.08371079307693,390.1116143907692,388.13951798846153,386.16742158615386,384.19532518384614,382.22322878153847,380.2511323792308,378.27903597692307,376.3069395746154,374.33484317230767,{"y":372.36274677,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":445.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":391.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€527.72

Average Price Target€462.03

Lowest Price Target€372.36

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

€437.38→€499.02

Buy

19.42%

Upside

Reiterated

02/17/26

Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. WainwrightVertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright

Whitney Ijem

Canaccord Genuity

€347.03→€372.36

Hold

-10.89%

Downside

Reiterated

02/17/26

Vertex Pharmaceuticals price target raised to $441 from $411 at CanaccordVertex Pharmaceuticals price target raised to $441 from $411 at Canaccord

Eliana Merle

Barclays

€512.53

Buy

22.66%

Upside

Reiterated

02/17/26

Vertex Pharmaceuticals (VRTX) Gets a Buy from Barclays

Naz Rahman

Maxim Group

Hold

―

Reiterated

02/17/26

Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Labcorp Holdings (NYSE: LH) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Joon Lee

Truist Financial

Buy

―

Reiterated

02/13/26

Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Artivion (AORT)

Myles Minter

William Blair

Buy

―

Reiterated

02/13/26

We continue to believe Alyftrek and follow-on CFTR correctors will maintain Vertex’s leadership position in CF ahead of competitor clinical data this year. Beyond CF, we view both Journavx and Casgevy as at relative inflection points as Journavx weans off its patient support program to enable more favorable gross-to-net pricing and Casgevy revenues remain volatile amid new patient uptake dynamics. Together these products are guided to do at least $500 million in revenue in 2026 (more than 185% year-over-year growth).

Joseph Stringer

Needham

Hold

―

Reiterated

02/13/26

Balancing Solid CF Revenue With Kidney Pipeline Uncertainty: Why Stringer Maintains a Hold on Vertex

Cory Kasimov

Evercore ISI

€447.51

Buy

7.10%

Upside

Reiterated

02/13/26

Vertex Pharmaceuticals (VRTX) Receives a Buy from Evercore ISI

Terence Flynn

Morgan Stanley

€476.22→€481.29

Buy

15.18%

Upside

Reiterated

02/13/26

Morgan Stanley Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Paul Matteis

Stifel Nicolaus

€375.74→€393.47

Hold

-5.83%

Downside

Reiterated

02/13/26

Vertex Pharmaceuticals price target raised to $466 from $445 at StifelVertex Pharmaceuticals price target raised to $466 from $445 at Stifel

Jay Olson

Oppenheimer

€455.95

Buy

9.12%

Upside

Upgraded

02/13/26

Vertex Pharmaceuticals upgraded to Outperform from Perform at OppenheimerVertex Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

Carter Gould

Cantor Fitzgerald

€409.51→€498.17

Buy

19.22%

Upside

Reiterated

02/13/26

Cantor Fitzgerald Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Tazeen Ahmad

Bank of America Securities

Buy

―

Reiterated

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (NYSE: OGN), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Vertex Pharmaceuticals (NASDAQ: VRTX)

William Pickering

Bernstein

€482.97→€487.2

Buy

16.60%

Upside

Assigned

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (NASDAQ: ALGN), Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE)

Louise Chen

Scotiabank

€417.96→€471.15

Buy

12.76%

Upside

Reiterated

02/13/26

Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

€437.38→€499.02

Buy

19.42%

Upside

Reiterated

02/17/26

Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. WainwrightVertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright

Whitney Ijem

Canaccord Genuity

€347.03→€372.36

Hold

-10.89%

Downside

Reiterated

02/17/26

Vertex Pharmaceuticals price target raised to $441 from $411 at CanaccordVertex Pharmaceuticals price target raised to $441 from $411 at Canaccord

Eliana Merle

Barclays

€512.53

Buy

22.66%

Upside

Reiterated

02/17/26

Vertex Pharmaceuticals (VRTX) Gets a Buy from Barclays

Naz Rahman

Maxim Group

Hold

―

Reiterated

02/17/26

Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Labcorp Holdings (NYSE: LH) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Joon Lee

Truist Financial

Buy

―

Reiterated

02/13/26

Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Artivion (AORT)

Myles Minter

William Blair

Buy

―

Reiterated

02/13/26

Joseph Stringer

Needham

Hold

―

Reiterated

02/13/26

Balancing Solid CF Revenue With Kidney Pipeline Uncertainty: Why Stringer Maintains a Hold on Vertex

Cory Kasimov

Evercore ISI

€447.51

Buy

7.10%

Upside

Reiterated

02/13/26

Vertex Pharmaceuticals (VRTX) Receives a Buy from Evercore ISI

Terence Flynn

Morgan Stanley

€476.22→€481.29

Buy

15.18%

Upside

Reiterated

02/13/26

Morgan Stanley Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Paul Matteis

Stifel Nicolaus

€375.74→€393.47

Hold

-5.83%

Downside

Reiterated

02/13/26

Vertex Pharmaceuticals price target raised to $466 from $445 at StifelVertex Pharmaceuticals price target raised to $466 from $445 at Stifel

Jay Olson

Oppenheimer

€455.95

Buy

9.12%

Upside

Upgraded

02/13/26

Vertex Pharmaceuticals upgraded to Outperform from Perform at OppenheimerVertex Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

Carter Gould

Cantor Fitzgerald

€409.51→€498.17

Buy

19.22%

Upside

Reiterated

02/13/26

Cantor Fitzgerald Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Tazeen Ahmad

Bank of America Securities

Buy

―

Reiterated

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (NYSE: OGN), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Vertex Pharmaceuticals (NASDAQ: VRTX)

William Pickering

Bernstein

€482.97→€487.2

Buy

16.60%

Upside

Assigned

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (NASDAQ: ALGN), Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE)

Louise Chen

Scotiabank

€417.96→€471.15

Buy

12.76%

Upside

Reiterated

02/13/26

Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months

xxx

Success Rate

21/29 ratings generated profit

Average Return

+7.07%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.41% of your transactions generating a profit, with an average return of +7.07% per trade.

1 Year

Salveen RichterGoldman Sachs

Success Rate

15/18 ratings generated profit

Average Return

+11.57%

a rating ―

Copying Salveen Richter's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +11.57% per trade.

2 Years

xxx

Success Rate

33/37 ratings generated profit

Average Return

+19.54%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 89.19% of your transactions generating a profit, with an average return of +19.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VX1 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VX1 has received 49 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. VX1 average Analyst price target in the past 3 months is 462.03.

Each month's total comprises the sum of three months' worth of ratings.

VX1 Financial Forecast

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is €3.73 with a range of €3.10 to €4.15. The previous quarter’s EPS was €4.25. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is €2.59B with a range of €2.45B to €2.73B. The previous quarter’s sales results were €2.72B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 462.03.

What is DE:VX1’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals has 10.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Vertex Pharmaceuticals a Buy, Sell or Hold?

Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 21 buy ratings, 4 hold ratings and 0 sell ratings.

What is Vertex Pharmaceuticals’s share price target?

The average share price target for Vertex Pharmaceuticals is 462.03. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €527.72 ,and the lowest forecast is €372.36. The average share price target represents 10.57% Increase from the current price of €417.85.

What do analysts say about Vertex Pharmaceuticals?

Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of Vertex Pharmaceuticals?

To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

VX1 Analyst Ratings

VX1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VX1 Analyst Recommendation Trends

VX1 Financial Forecast

VX1 Earnings Forecast

VX1 Sales Forecast

VX1 Stock Forecast FAQ

Detailed List of Analyst Forecasts